Novavax | NVAX - Actif À Court Terme





Actif À Court Terme Changement Date
Adma Biologics USD 466.51M 63.86M 2025-12
Agenus USD 133.44M 514K 2025-12
AstraZeneca USD 29.61B 890M 2026-03
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Cassava Sciences USD 97.71M 11.2M 2025-12
Geron USD 520.27M 2.07M 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
MannKind USD 291.58M 67.26M 2025-12
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Moderna USD 5.77B 774M 2026-03
Novartis USD 30.46B 2.26B 2025-12
Novavax USD 978.28M 3.69M 2025-12
Pfizer USD 42.82B 76M 2026-03
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
TG Therapeutics USD 630.76M 31M 2025-12